Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2005

01-12-2005 | Original Paper

Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo

Authors: Marina Pavlak, Ranko Stojković, Matea Radačić-Aumiler, Jelena Kašnar-Šamprec, Jure Jerčić, Ksenija Vlahović, Biserka Žinić, Marko Radačić

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2005

Login to get access

Abstract

Purpose: The purpose of this study was to investigate in vivo antitumor activity of newly synthesized N-sulfonylpyrimidine derivatives 1-(p-toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4H×HCl) and zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K). Materials and methods: In order to do that we have used mouse anaplastic mammary carcinoma (AMCa). Tumor cells (106) in a volume of 0.02 ml were transplanted into the thigh of the right hind leg of CBA mice. All compounds were dissolved in distilled water immediately before injecting to animals. Results: Antitumor effect of these compounds depends on drug doses and time interval between tumor transplantation and drug application. Further the efficacy of these compounds depends on number of drug injections, i. e. whether drug was given in single or in multiple doses. Multiple doses of 400 mg/kg of 1-(p-toluenesulfonyl)cytosine (4H) showed good antitumor effect when applied on day 1, 3, 5, 7 and 9 after tumor transplantation. Still good but slightly lower antitumor effect was also achieved when that compound was given in a single dose (1,200 mg/kg) on day 1 after tumor transplantation. The longest period of tumor growth time was obtained after application of 1-(p-toluenesulfonyl)cytosine hydrochloride (4H×HCl) given as a single dose (300 mg/kg) on day 1 or on day 6 after tumor implantation. However, antitumor effect of zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K) was very strong when 300 mg/kg was given on day 1 or day 6, while this effect was slightly lower when drug (200 mg/kg/inj) was given on day 1, 3, 5, 7 and 9 or on day 6, 8, 10, 12 and 14. Conclusion: In this work it has been found that N-1-sulfonylcytosine derivatives have strong antitumor activity against mouse mammary carcinoma which is a good reason for further research of these compounds both in experimental and preclinical studies.
Literature
go back to reference Ardalan BM, Buscaglia D, Schein PS (1978) Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response. Biochem Pharmacol 27:2009–2013CrossRefPubMed Ardalan BM, Buscaglia D, Schein PS (1978) Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response. Biochem Pharmacol 27:2009–2013CrossRefPubMed
go back to reference Ardalan B, Villacorte D, Heck D, Corbett T (1982) Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. Biochem Pharmacol 31:1989–1992CrossRefPubMed Ardalan B, Villacorte D, Heck D, Corbett T (1982) Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. Biochem Pharmacol 31:1989–1992CrossRefPubMed
go back to reference Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G (2003) A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma. Final analysis with 10-year follow-up. Cancer 97:2716–2723CrossRefPubMed Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G (2003) A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma. Final analysis with 10-year follow-up. Cancer 97:2716–2723CrossRefPubMed
go back to reference Badawey ESAM (1996) Synthesis and in vitro evaluation of some new pyrimidines and related condensed ring system as potential anticancer agents. J Heterocycl Chem 33:229–233CrossRef Badawey ESAM (1996) Synthesis and in vitro evaluation of some new pyrimidines and related condensed ring system as potential anticancer agents. J Heterocycl Chem 33:229–233CrossRef
go back to reference Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A (2004) A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 100:1358–1364CrossRefPubMed Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A (2004) A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer 100:1358–1364CrossRefPubMed
go back to reference Bibby MC, Double JA, McCormick JE, McElhinney RS, Radaèić M, Pratesi G, Dumont P (1993) Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5substituent and the point of attachment (N1 or N3) of the uracil moiety in seconucleoside nitrosoureas. Anti Cancer Drug Des 8:115–128 Bibby MC, Double JA, McCormick JE, McElhinney RS, Radaèić M, Pratesi G, Dumont P (1993) Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5substituent and the point of attachment (N1 or N3) of the uracil moiety in seconucleoside nitrosoureas. Anti Cancer Drug Des 8:115–128
go back to reference Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur R (1999) Fluoropyrimidine: a critical evaluation. Oncology 57 (Suppl 1):2–8CrossRefPubMed Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur R (1999) Fluoropyrimidine: a critical evaluation. Oncology 57 (Suppl 1):2–8CrossRefPubMed
go back to reference Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoidi L, Carmisa R, Bruzzi P (2002) Randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer 95:228–235CrossRefPubMed Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoidi L, Carmisa R, Bruzzi P (2002) Randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer 95:228–235CrossRefPubMed
go back to reference Emerman JT, Siemiatkowski (1984) Effects of endocrine regulation of growth of a mouse mammary tumor on its sensitivity to chemotherapy. Cancer Res 44:1327–1332PubMed Emerman JT, Siemiatkowski (1984) Effects of endocrine regulation of growth of a mouse mammary tumor on its sensitivity to chemotherapy. Cancer Res 44:1327–1332PubMed
go back to reference Fichtner I, Tanneberger S (1987) Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. Anticancer Res 7:227–233PubMed Fichtner I, Tanneberger S (1987) Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. Anticancer Res 7:227–233PubMed
go back to reference Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridin and docetaxel in breast cancer models. Clin Cancer Res 7:1079–1086PubMed Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridin and docetaxel in breast cancer models. Clin Cancer Res 7:1079–1086PubMed
go back to reference Glavaš-Obrovac Lj, Karner I, Žinić B, Pavelić K (2001) Antineoplastic activity of novel N-1-sulfonylpyrimidine derivatives. Anticancer Res 21:1979–1986PubMed Glavaš-Obrovac Lj, Karner I, Žinić B, Pavelić K (2001) Antineoplastic activity of novel N-1-sulfonylpyrimidine derivatives. Anticancer Res 21:1979–1986PubMed
go back to reference Hatse S, De Clercq E, Balzarini J (1999) Impact of 9-(2-phosphonylmethoxiethyl) adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells. FEBS Lett 445:92–97CrossRefPubMed Hatse S, De Clercq E, Balzarini J (1999) Impact of 9-(2-phosphonylmethoxiethyl) adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells. FEBS Lett 445:92–97CrossRefPubMed
go back to reference Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A (1996) Nucleosides and nucleotides 158. 1-(3-C-ethynyl-β-D-ribopenthofuranosyl)-cytosine, 1-(3-C-ethynyl-β-D-ribopenthofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39:5005–5011CrossRefPubMed Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A (1996) Nucleosides and nucleotides 158. 1-(3-C-ethynyl-β-D-ribopenthofuranosyl)-cytosine, 1-(3-C-ethynyl-β-D-ribopenthofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39:5005–5011CrossRefPubMed
go back to reference Isaac N, Panzarella T, Lau A, Mayers C, Kirkbride P, Tannock IF, Vallis KA (2002) Concurrent cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma. Cancer 95:695–703CrossRef Isaac N, Panzarella T, Lau A, Mayers C, Kirkbride P, Tannock IF, Vallis KA (2002) Concurrent cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma. Cancer 95:695–703CrossRef
go back to reference Kašnar B, Krizmanić I, Žinić M (1997) Synthesis of the sulfonylpyrimidine derivatives as a new type of sulfonylcycloureas. Nucleos Nucleot 16:1067–1071CrossRef Kašnar B, Krizmanić I, Žinić M (1997) Synthesis of the sulfonylpyrimidine derivatives as a new type of sulfonylcycloureas. Nucleos Nucleot 16:1067–1071CrossRef
go back to reference Kerr LR, Grimm MS, Silva WA, Weinberg J, Emerman JT (1997) Effects of social housing condition on the response of the Shionogi mouse mammary carcinoma (SC115) to chemotherapy. Cancer Res 57:1124–1128PubMed Kerr LR, Grimm MS, Silva WA, Weinberg J, Emerman JT (1997) Effects of social housing condition on the response of the Shionogi mouse mammary carcinoma (SC115) to chemotherapy. Cancer Res 57:1124–1128PubMed
go back to reference Kerr LR, Wilkinson DA, Emerman JT, Weinberg J (1999) Interactive effects of psychosocial stressors and gender on mouse mammary tumor growth. Physiol Behav 66:277–284CrossRefPubMed Kerr LR, Wilkinson DA, Emerman JT, Weinberg J (1999) Interactive effects of psychosocial stressors and gender on mouse mammary tumor growth. Physiol Behav 66:277–284CrossRefPubMed
go back to reference Kerr LR, Hundal R, Silva WA, Emermann JT, Weinberg J (2001) Effects of social housing condition on chemotherapeutic efficacy in a Shionogi carcinoma (SC115) mouse tumor model: Influences of temporal factors, tumor size and tumor growth rate. Psychosom Med 63:973–984PubMed Kerr LR, Hundal R, Silva WA, Emermann JT, Weinberg J (2001) Effects of social housing condition on chemotherapeutic efficacy in a Shionogi carcinoma (SC115) mouse tumor model: Influences of temporal factors, tumor size and tumor growth rate. Psychosom Med 63:973–984PubMed
go back to reference Kuhn JG (2001) Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 35:217–227CrossRefPubMed Kuhn JG (2001) Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 35:217–227CrossRefPubMed
go back to reference Lendnicer D, Mitscher LD (1977) The organic chemistry of drug synthesis, vol 1. Wiley, New York, pp 120–132 Lendnicer D, Mitscher LD (1977) The organic chemistry of drug synthesis, vol 1. Wiley, New York, pp 120–132
go back to reference MacCoss M, Robins MJ (1990) Chemistry of antitumor agents. In: Wilman DEV (ed) Blackie and Son, UK, p 261 MacCoss M, Robins MJ (1990) Chemistry of antitumor agents. In: Wilman DEV (ed) Blackie and Son, UK, p 261
go back to reference Malet-Martino M, Martino R (2002) Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7:288–323CrossRefPubMed Malet-Martino M, Martino R (2002) Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7:288–323CrossRefPubMed
go back to reference Martin DS, Fugmann RA, Stolfi RL, Hayworth PE (1975) Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 5:89–109 Martin DS, Fugmann RA, Stolfi RL, Hayworth PE (1975) Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 5:89–109
go back to reference McElhinney RS, McCormick JE, Bibby MC, Double JA, Atassi G, Dumont P, Pratesi G, Radaèić M (1989) Nucleoside analogues. 9. Seco-nucleoside analogues of some 5fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity. Anti Cancer Drug Des 4:191–207 McElhinney RS, McCormick JE, Bibby MC, Double JA, Atassi G, Dumont P, Pratesi G, Radaèić M (1989) Nucleoside analogues. 9. Seco-nucleoside analogues of some 5fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity. Anti Cancer Drug Des 4:191–207
go back to reference Piccart MJ, Cardoso F (2003) progress in systemic therapy for breast cancer: an overview and perspectives (Review). EJP 1(suppl 2):56–69 Piccart MJ, Cardoso F (2003) progress in systemic therapy for breast cancer: an overview and perspectives (Review). EJP 1(suppl 2):56–69
go back to reference Radaèić M, Boranić M, Bašić I (1982) A mouse mammary carcinoma as a model for evaluation of drug effects on primary tumour growth and metastases. In: Lapis K, Jeney A (eds) Tumour progression and markers. Kugler Public, Amsterdam, pp 217–223 Radaèić M, Boranić M, Bašić I (1982) A mouse mammary carcinoma as a model for evaluation of drug effects on primary tumour growth and metastases. In: Lapis K, Jeney A (eds) Tumour progression and markers. Kugler Public, Amsterdam, pp 217–223
go back to reference Radaèić M, Blašković T, Boranić M, Jerčić J, Čulo J, Eisenbrand G, Bašić I (1989) Curability of transplantable mammary carcinoma of mice with nitrosourea derivates and hyperthermia. Period Biol 91: 62–63 Radaèić M, Blašković T, Boranić M, Jerčić J, Čulo J, Eisenbrand G, Bašić I (1989) Curability of transplantable mammary carcinoma of mice with nitrosourea derivates and hyperthermia. Period Biol 91: 62–63
go back to reference Radaèić M. (1995) New approaches to the treatment of malignant diseases: hyperthermia in cancer therapy. Libri Oncol 24:89–102 Radaèić M. (1995) New approaches to the treatment of malignant diseases: hyperthermia in cancer therapy. Libri Oncol 24:89–102
go back to reference Rastum YM (2004) Thymidylate synthase: a critical target in cancer therapy. Front Biosci 9:2467–2473PubMedCrossRef Rastum YM (2004) Thymidylate synthase: a critical target in cancer therapy. Front Biosci 9:2467–2473PubMedCrossRef
go back to reference Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine Clin Pharmacokinet 40:85–104 (Review)PubMedCrossRef Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine Clin Pharmacokinet 40:85–104 (Review)PubMedCrossRef
go back to reference Reigner B, Watanabe T, Schuller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 52:193–201CrossRefPubMed Reigner B, Watanabe T, Schuller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 52:193–201CrossRefPubMed
go back to reference Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232 (Review)CrossRefPubMed Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232 (Review)CrossRefPubMed
go back to reference Robins RK, Revankar GR (1988) Antiviral drug development. In: De Clercq E, Walker RT (eds) Plenum Press, New York, p 11 Robins RK, Revankar GR (1988) Antiviral drug development. In: De Clercq E, Walker RT (eds) Plenum Press, New York, p 11
go back to reference Schilsky RL (2000) Pharmacology and clinical status of capecitabine. Oncology 14:1297–1306PubMed Schilsky RL (2000) Pharmacology and clinical status of capecitabine. Oncology 14:1297–1306PubMed
go back to reference Schmaehl D (1985) Maligni tumori. Nastanak, razvoj, kemoterapija, 3rd edn. Universal, Tuzla Schmaehl D (1985) Maligni tumori. Nastanak, razvoj, kemoterapija, 3rd edn. Universal, Tuzla
go back to reference Tada M (1975) Antineoplastic agents. Synthesis of some 1-substituted 5-fluorouracil derivatives. Chem Lett 2: 129–130CrossRef Tada M (1975) Antineoplastic agents. Synthesis of some 1-substituted 5-fluorouracil derivatives. Chem Lett 2: 129–130CrossRef
go back to reference Tada M (1976) 5-Fluorouracil derivatives. (Mitsui Selyaku Kogyo Co., Ltd.) US 3,971,784 July 27, 1976 Tada M (1976) 5-Fluorouracil derivatives. (Mitsui Selyaku Kogyo Co., Ltd.) US 3,971,784 July 27, 1976
go back to reference Takahashi T, Nakashima A, Kanazawa J, Yamaguchi K, Akinaga S, Tamaoki T, Okabe M (1998) Metabolism and ribonucleotide reductase inhibition of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101, 731, in human cervical carcinoma HeLa S3 cells. Cancer Chemother Pharmacol 41:268–274CrossRefPubMed Takahashi T, Nakashima A, Kanazawa J, Yamaguchi K, Akinaga S, Tamaoki T, Okabe M (1998) Metabolism and ribonucleotide reductase inhibition of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101, 731, in human cervical carcinoma HeLa S3 cells. Cancer Chemother Pharmacol 41:268–274CrossRefPubMed
go back to reference Yamashita JL, Yamawaki I, Ueda S, Yasumoto M, Unemi N, Hashimoto S (1982) Studies on antitumor agents. Synthesis and antitumor activities of 5-fluorouracil. Chem Pharm Bull 30:4258–4267PubMed Yamashita JL, Yamawaki I, Ueda S, Yasumoto M, Unemi N, Hashimoto S (1982) Studies on antitumor agents. Synthesis and antitumor activities of 5-fluorouracil. Chem Pharm Bull 30:4258–4267PubMed
go back to reference Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F (2003) The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug and cyclophosphamide for metastatic breast cancer. Br J Cancer 89:1627–1632CrossRefPubMed Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F (2003) The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug and cyclophosphamide for metastatic breast cancer. Br J Cancer 89:1627–1632CrossRefPubMed
go back to reference Wagstaff AJ, Ibbotson T, Goa KL (2003) Capecitabine—a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63:217–236PubMedCrossRef Wagstaff AJ, Ibbotson T, Goa KL (2003) Capecitabine—a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63:217–236PubMedCrossRef
go back to reference Winer EP (1998) Oral 5-fluorouracil analogues in the treatment of breast cancer. Oncology 12 (10 Suppl 7):39–43PubMed Winer EP (1998) Oral 5-fluorouracil analogues in the treatment of breast cancer. Oncology 12 (10 Suppl 7):39–43PubMed
go back to reference Žinić B, Krizmanić I, Vikić-Topić D, Žinić M (1999) 5-Bromo- and 5-iodo-N-1-sulfonylated cytosine derivatives. Exclusive formation of keto-imino tautomers. Croat Chem Acta 72:957–966 Žinić B, Krizmanić I, Vikić-Topić D, Žinić M (1999) 5-Bromo- and 5-iodo-N-1-sulfonylated cytosine derivatives. Exclusive formation of keto-imino tautomers. Croat Chem Acta 72:957–966
go back to reference Žinić B, Žinić M, Krizmanić I (2003) Sulfonylpyrimidine derivatives with anticancer activity. (Proprietor: Ruđer Bošković Institute) EP 0 877 022 B1 Žinić B, Žinić M, Krizmanić I (2003) Sulfonylpyrimidine derivatives with anticancer activity. (Proprietor: Ruđer Bošković Institute) EP 0 877 022 B1
Metadata
Title
Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo
Authors
Marina Pavlak
Ranko Stojković
Matea Radačić-Aumiler
Jelena Kašnar-Šamprec
Jure Jerčić
Ksenija Vlahović
Biserka Žinić
Marko Radačić
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-005-0026-z

Other articles of this Issue 12/2005

Journal of Cancer Research and Clinical Oncology 12/2005 Go to the issue